These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 35055707)
1. Symptomatic SARS-CoV-2 Infection with Ageusia after Two mRNA Vaccine Doses. Caponio VCA; Lipsi MR; Fortunato F; Arena F; Lo Muzio L Int J Environ Res Public Health; 2022 Jan; 19(2):. PubMed ID: 35055707 [TBL] [Abstract][Full Text] [Related]
2. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines. Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073 [TBL] [Abstract][Full Text] [Related]
3. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study. Olariu TR; Ursoniu S; Marincu I; Lupu MA Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275 [No Abstract] [Full Text] [Related]
4. Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses. Gounant V; Ferré VM; Soussi G; Charpentier C; Flament H; Fidouh N; Collin G; Namour C; Assoun S; Bizot A; Brouk Z; Vicaut E; Teixeira L; Descamps D; Zalcman G J Thorac Oncol; 2022 Feb; 17(2):239-251. PubMed ID: 34798306 [TBL] [Abstract][Full Text] [Related]
5. Investigation of an outbreak of symptomatic SARS-CoV-2 VOC 202012/01-lineage B.1.1.7 infection in healthcare workers, Italy. Loconsole D; Sallustio A; Accogli M; Leaci A; Sanguedolce A; Parisi A; Chironna M Clin Microbiol Infect; 2021 Aug; 27(8):1174.e1-1174.e4. PubMed ID: 33984489 [TBL] [Abstract][Full Text] [Related]
6. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women. Goldshtein I; Nevo D; Steinberg DM; Rotem RS; Gorfine M; Chodick G; Segal Y JAMA; 2021 Aug; 326(8):728-735. PubMed ID: 34251417 [TBL] [Abstract][Full Text] [Related]
7. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines. Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093 [TBL] [Abstract][Full Text] [Related]
8. Development of Graves' Disease After SARS-CoV-2 mRNA Vaccination: A Case Report and Literature Review. Lui DTW; Lee KK; Lee CH; Lee ACH; Hung IFN; Tan KCB Front Public Health; 2021; 9():778964. PubMed ID: 34888290 [No Abstract] [Full Text] [Related]
9. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data. Paris C; Perrin S; Hamonic S; Bourget B; Roué C; Brassard O; Tadié E; Gicquel V; Bénézit F; Thibault V; Garlantézec R; Tattevin P Clin Microbiol Infect; 2021 Nov; 27(11):1699.e5-1699.e8. PubMed ID: 34265462 [TBL] [Abstract][Full Text] [Related]
11. Humoral immune response after different SARS-CoV-2 vaccination regimens. Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798 [TBL] [Abstract][Full Text] [Related]
12. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
13. De Novo Minimal Change Disease following Vaccination with the Pfizer/BioNTech SARS-CoV-2 Vaccine in a Living Kidney Donor. Marinaki S; Kolovou K; Liapis G; Skalioti C; Tsiakas S; Boletis I Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056345 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519 [TBL] [Abstract][Full Text] [Related]
16. Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic. Brehm TT; Thompson M; Ullrich F; Schwinge D; Addo MM; Spier A; Knobloch JK; Aepfelbacher M; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J Int J Hyg Environ Health; 2021 Sep; 238():113851. PubMed ID: 34601375 [TBL] [Abstract][Full Text] [Related]
17. Anosmia or Ageusia Following COVID-19 Vaccination: A Systematic Review. Arabzadeh Bahri R; Esmaeilpur Abianeh F; Peisepar M; Hadi R; Basti FA; Maleki S; Radkhah H Ear Nose Throat J; 2024 Jun; 103(1_suppl):164S-170S. PubMed ID: 38411125 [No Abstract] [Full Text] [Related]
18. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection. Costanzo M; De Giglio MAR; Roviello GN Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678 [TBL] [Abstract][Full Text] [Related]